ImmuneOnco
Develop first-in-class drugs
For the benefit of cancer patients

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. was established in the PRC in June 2015. ImmuneOnco is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. ImmuneOnco is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. Currently approved immunotherapies primarily focus on the adaptive immune system and are often confronted with limited clinical benefits due to low response rates and inevitable drug resistance and/or relapse in many cancer indications. Harnessing both the innate and adaptive immune systems allows us to overcome the limitations of current T-cell-based immunotherapies and address substantial unmet medical needs of cancer patients.

Develop first-in-class drugs
A fully-integrated R&D platform
Discover and develop novel immuno-oncology therapies

Integrated proprietary R&D engine anchored around our deep understanding of tumor immunology, continuously driving the discovery and development of immunotherapies.

For the benefit of cancer patients
Independent innovation
Global layout

Harnessing both the innate and adaptive immune systems allows us to overcome the limitations of current T-cell-based immunotherapies and address significant unmet medical needs of cancer patients.

0.085621s